Vigil Neuroscience: losses, no revenue, and funding pressure

Vigil says it has incurred significant operating losses since inception.

Vigil reported no revenue through March 31, 2025.

The March 31, 2025 10-Q says there is substantial doubt about Vigil’s ability to continue as a going concern.

Vigil said its cash, cash equivalents, and marketable securities were expected to fund operations into 2026.

Vigil expects to need additional financing to support operations and business objectives.